NASDAQ:EDIT Editas Medicine (EDIT) Stock Forecast, Price & News $9.10 +0.02 (+0.22%) (As of 05/26/2023 08:46 PM ET) Add Compare Share Share Today's Range$8.94▼$9.2150-Day Range$6.36▼$10.2852-Week Range$6.33▼$19.97Volume1.06 million shsAverage Volume2.00 million shsMarket Capitalization$627.90 millionP/E RatioN/ADividend YieldN/APrice Target$15.86 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Editas Medicine MarketRank™ ForecastAnalyst RatingHold2.31 Rating ScoreUpside/Downside74.3% Upside$15.86 Price TargetShort InterestBearish29.32% of Shares Sold ShortDividend StrengthN/ASustainability-0.56Upright™ Environmental ScoreNews Sentiment0.76Based on 3 Articles This WeekInsider TradingSelling Shares$19,777 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.04) to ($3.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.83 out of 5 starsMedical Sector755th out of 1,009 stocksBiological Products, Except Diagnostic Industry119th out of 167 stocks 3.2 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 5 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.86, Editas Medicine has a forecasted upside of 74.3% from its current price of $9.10.Amount of Analyst CoverageEditas Medicine has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted29.32% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Editas Medicine has recently increased by 7.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 76.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.56. Previous Next 1.5 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Editas Medicine this week, compared to 3 articles on an average week.Search InterestOnly 23 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,777.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions69.67% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($3.04) to ($3.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Editas Medicine (NASDAQ:EDIT) StockEditas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.Read More Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Stock News HeadlinesMay 23, 2023 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Stock Rating Lowered by StockNews.comMay 19, 2023 | finanznachrichten.deEditas Medicine, Inc.: Editas Medicine Reports Inducement Grant to New Chief Financial OfficerMay 30, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 18, 2023 | finance.yahoo.comEditas Medicine Reports Inducement Grant to New Chief Financial OfficerMay 17, 2023 | bizjournals.comEditas loses another executive — the 9th in 5 years — amid new focusMay 17, 2023 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Shares Up 7.8%May 16, 2023 | seekingalpha.comEditas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference 2023 TranscriptMay 15, 2023 | msn.comOppenheimer Reiterates Editas Medicine (EDIT) Perform RecommendationMay 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 15, 2023 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Upgraded at StockNews.comMay 13, 2023 | seekingalpha.comEditas Medicine, Inc. (EDIT) Bank of America Global Healthcare Conference Call TranscriptMay 13, 2023 | americanbankingnews.comCantor Fitzgerald Comments on Editas Medicine, Inc.'s FY2023 Earnings (NASDAQ:EDIT)May 10, 2023 | finance.yahoo.comIndustry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%May 10, 2023 | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives $15.33 Consensus Target Price from AnalystsMay 9, 2023 | markets.businessinsider.comOppenheimer Sticks to Their Hold Rating for Editas Medicine (EDIT)May 9, 2023 | businesswire.comNutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directorsMay 9, 2023 | msn.comUnusual Call Option Trade in Editas Medicine (EDIT) Worth $13.32KMay 9, 2023 | msn.comCredit Suisse Maintains Editas Medicine (EDIT) Neutral RecommendationMay 9, 2023 | msn.comRBC Capital Maintains Editas Medicine (EDIT) Sector Perform RecommendationMay 8, 2023 | markets.businessinsider.com6 Analysts Have This to Say About Editas MedicineMay 8, 2023 | forbes.comThe Scientist Turned Biotech Empresario Who Changed How We Look At Gene EditingMay 8, 2023 | finance.yahoo.comEditas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock UpMay 8, 2023 | markets.businessinsider.comEditas Medicine (EDIT) Gets a Hold from Credit SuisseMay 8, 2023 | msn.comChardan Capital Reiterates Editas Medicine (EDIT) Buy RecommendationMay 5, 2023 | msn.comEditas Medicine: Pioneering Gene-Editing Solutions For Inherited Blood Disorders And BeyondMay 5, 2023 | finanznachrichten.deEditas Medicine, Inc.: Editas Medicine Announces First Quarter 2023 Results and Business UpdatesMay 5, 2023 | msn.comEditas Medicine: Q1 Earnings InsightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Company Calendar Last Earnings5/05/2023Today5/29/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees264Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.86 High Stock Price Forecast$35.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+74.3%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-220,430,000.00 Net Margins-960.70% Pretax Margin-960.70% Return on Equity-56.20% Return on Assets-41.90% Debt Debt-to-Equity RatioN/A Current Ratio5.68 Quick Ratio5.68 Sales & Book Value Annual Sales$19.71 million Price / Sales31.86 Cash FlowN/A Price / Cash FlowN/A Book Value$5.25 per share Price / Book1.73Miscellaneous Outstanding Shares69,000,000Free Float67,478,000Market Cap$627.90 million OptionableOptionable Beta1.86 Key ExecutivesGilmore O’NeillPresident, Chief Executive Officer & DirectorHarry R. GillSenior Vice President-OperationsErick J. LuceraChief Financial Officer & Executive Vice PresidentBruce E. EatonExecutive VP, Chief Business & Technology OfficerMei BaisongChief Medical Officer & Senior Vice PresidentKey CompetitorsAlectorNASDAQ:ALECNovavaxNASDAQ:NVAXHilleVaxNASDAQ:HLVX4D Molecular TherapeuticsNASDAQ:FDMTMesoblastNASDAQ:MESOView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,664 shares on 5/26/2023Ownership: 0.019%Ameriprise Financial Inc.Sold 135,769 shares on 5/22/2023Ownership: 0.085%JPMorgan Chase & Co.Sold 49,703 shares on 5/18/2023Ownership: 1.642%New York State Common Retirement FundSold 9,733 shares on 5/18/2023Ownership: 0.057%Mercer Global Advisors Inc. ADVBought 15,639 shares on 5/16/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions EDIT Stock - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price forecast for 2023? 13 brokerages have issued 1-year price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they expect the company's stock price to reach $15.86 in the next twelve months. This suggests a possible upside of 74.3% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2023? Editas Medicine's stock was trading at $8.87 at the beginning of the year. Since then, EDIT shares have increased by 2.6% and is now trading at $9.10. View the best growth stocks for 2023 here. Are investors shorting Editas Medicine? Editas Medicine saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 20,230,000 shares, an increase of 7.3% from the April 30th total of 18,860,000 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is presently 11.0 days. View Editas Medicine's Short Interest. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Friday, May, 5th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.08. The firm had revenue of $9.90 million for the quarter, compared to analysts' expectations of $3.29 million. Editas Medicine had a negative trailing twelve-month return on equity of 56.20% and a negative net margin of 960.70%. The company's revenue for the quarter was up 45.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.74) EPS. What ETFs hold Editas Medicine's stock? ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Horizon Kinetics Medical ETF (MEDX), AXS Green Alpha ETF (NXTE), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ROBO Global Healthcare Technology and Innovation ETF (HTEC). What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (11.83%), BlackRock Inc. (10.75%), Dimensional Fund Advisors LP (2.34%), Geode Capital Management LLC (2.10%), JPMorgan Chase & Co. (1.64%) and Pictet Asset Management SA (1.53%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $9.10. How much money does Editas Medicine make? Editas Medicine (NASDAQ:EDIT) has a market capitalization of $627.90 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis. How many employees does Editas Medicine have? The company employs 264 workers across the globe. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com. This page (NASDAQ:EDIT) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.